COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Abstract Text:

I Cheng,X Liu,S J Plummer,L M Krumroy,G Casey,J S Witte,

Collective evidence suggests that cyclooxygenase 2 (COX2) plays a role in prostate cancer risk. Cyclooxygenase 2 is the major enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of COX2 and long-term use of NSAIDs appears to modestly lower the risk of prostate cancer. We investigated whether common genetic variation in COX2 influences the risk of advanced prostate cancer. Nine single-nucleotide polymorphisms (SNPs) in COX2 were genotyped among 1012 men in our case-control study of advanced prostate cancer. Gene-environment interactions between COX2 polymorphisms and NSAID use were also evaluated. Information on NSAID use was obtained by questionnaire. Three SNPs demonstrated nominally statistically significant associations with prostate cancer risk, with the most compelling polymorphism (rs2745557) associated with a lower risk of disease (odds ratio (OR) GC vs GG=0.64; 95% confidence interval (CI): 0.49-0.84; P=0.002). We estimated through permutation analysis that a similarly strong result would occur by chance 2.7% of the time. Nonsteroidal anti-inflammatory drug use was associated with a lower risk of disease in comparison to no use (OR=0.67; 95% CI: 0.52-0.87). No significant statistical interaction between NSAID use and rs2745557 was observed (P=0.12). Our findings suggest that variation in COX2 is associated with prostate cancer risk.

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Publishing Authors By Initials

I Cheng,X Liu,SJ Plummer,LM Krumroy,G Casey,JS Witte,

For similar genetic phenomena: variation (genetics) research abstracts see: genetic phenomena: variation (genetics) research

PUBMED ID PMID:

MEDLINE DATE:

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: British journal of cancer

VOLUME: 97

Page Numbers: 557-61

Journal Abbreviation: Br. J. Cancer

ISSN: 0007-0920

DAY: 3

MONTH: 07

YEAR: 2007

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370635

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Keywords Mesh Terms:

KEYWORDS: Variation (Genetics)

MESH TERMS: pathology

Chemical & Substance for Abstract: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Information

Substance Name: Cyclooxygenase 2

Registry Number: EC 1.14.99.1

Grant and Affiliation Information for COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.

AFFILIATION: Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143-0794, USA.

Country: England

AGENCY: United States NCI

GRANT: R25T CA112355

ACRONYM: CA

MEDLINETA: Br J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk Related Publications

• Association of testis derived transcript gene variants and prostate cancer risk.
• COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.
• Enhanced Paracrine FGF10 Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial Androgen Receptor.
• Enriching the analysis of genomewide association studies with hierarchical modeling.
• Immunoglobulin-like transcripts as risk genes for autoimmunity.
• Isolation and functional characterization of murine prostate stem cells.
• Landmarks and advances in translational lymphology.
• MIC1 and IL1RN genetic variation and advanced prostate cancer risk.
• Model-related analysis of EEG burst patterns in sedated patients.
• Multiple prostate cancer risk variants on 8q24.
• Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha.
• Occurrence of the USA300 community-acquired Staphylococcus aureus clone in Austria.
• Plasma cell purification from murine bone marrow using a two-step isolation approach.
• Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis.
• Report of a case of acute hydramnios.
• Self-renewal and multilineage differentiation in vitro from murine prostate stem cells.
• Sensor, signal, and image informatics - state of the art and current topics.
• Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.
• Temporal characterization of short-pulse third-harmonic generation in an atomic gas by a transmission-grating Michelson interferometer.
• The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats.
• The effects of microenvironment and internal programming on plasma cell survival.
• Time-variant analysis of nonlinear stability and bispectral measures to quantify the development of fetal sleep States.
• Time-variant parametric estimation of transient quadratic phase couplings between heart rate components in healthy neonates.
• Toll-like receptor 4 genetic variation and advanced prostate cancer risk.
• Trans-fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant.
• Vitamin D receptor genotypes/haplotypes and prostate cancer risk.
• [In Process Citation]
• [In Process Citation]
• [Not Available.]
• [Premedication, preoperative and postoperative visits : Importance as reflected in anaesthesiology textbooks.]